Invitrogen™ Human BCL9L Synthetic Peptide

Catalog No.	Quantity
PEP1225	50 μg

Catalog No. PEP1225 Supplier Invitrogen™ Supplier No. PEP1225

Description

Synthetic Peptide

Bcl9L Synthetic Peptide, PEP-1225, from Invitrogen.

Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

Specifications

• Gene ID (Entrez): 283149
• Species: Human
• Purification Method: purified
• Accession Number: Q86UU0
• Common Name: Human BCL9L
• Concentration: 200 μg/mL
• Content And Storage: -20°C
• Description: Synthetic Peptide
• Format: Liquid
• Formulation: PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2
• For Use With (Application): Blocking Assay, Control
• Gene Symbol: BCL9L
• Lyophilized: No
• Preservative: 0.02% sodium azide
• Product Type: Peptide
• Quantity: 50 μg
• Regulatory Status: RUO - research use only
• Storage Buffer: PBS